Current and Upcoming Social Anxiety Disorder Studies
SAD Study: Phase 3, Randomized, Double-Blind, 2-arm, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an investigational medication for the Acute, As-Needed Treatment of Anxiety in Adults with SAD
Mechanism: negative allosteric modulator of the α7 nicotinic acetylcholine receptor
Age: 18 - 65
BMI: Not specified
Cannabis: None, cannot test + at screening
Therapy: No psychotherapy for anxiety within 60 days of screening
Exclusionary Diagnoses:
No lifetime history of bipolar disorders, schizophrenia, schizoaffective disorder, psychot
Mechanism: negative allosteric modulator of the α7 nicotinic acetylcholine receptor
Age: 18 - 65
BMI: Not specified
Cannabis: None, cannot test + at screening
Therapy: No psychotherapy for anxiety within 60 days of screening
Exclusionary Diagnoses:
No lifetime history of bipolar disorders, schizophrenia, schizoaffective disorder, psychotic disorders, anorexia, bulimia, body dysmorphic disorder, PTSD, ASD, OCD, or HIV
No primary psychiatric dx that takes precedent over SAD at screening
Additional Exclusion Criteria: Cannot have failed to respond to 2+ psychotropic treatments for SAD (not counted if medication was discontinued due to side effects)
Study Duration: 4 weeks
Payment: Clinic visits: $75 - 150, up to $375 if all visits are completed
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.